Viiv Healthcare conducted two identical, year-long trials — each involving about 500 patients — for its HIV pill dolutegravir. Results showed dolutegravir, when used with Johnson & Johnson’s rilpivirine, suppressed HIV just as well as conventional three- or four-drug treatment methods, according to the report.
Allowing patients to follow a treatment regimen of fewer drug combinations could help lower side effects of antiretroviral medicines, which often include nausea, diarrhea and bone-thinning, among others.
Dominique Limet, CEO of Viiv Healthcare, said the company expects to submit the two-drug combination to regulators in 2017. Both dolutegravir and rilpivirine are already sold as components of three- or four-drug combinations.
More articles on supply chain:
Supply chain tip of the week: How to put your supply chain on a ‘diet’
Survey: 19M Americans have purchased cheaper drugs across US borders
Opinion: 4 reasons drug prices will continue to rise in 2017
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
